A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market.

Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.

Download the PDF brochure: https://www.coherentmarketinsights.com/insight/request-pdf/2427

Market Dynamics

Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant drugs market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.
Such initiatives taken by companies is expected to lead to the development of new cough suppressant drugs.

For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.

High prevalence of cough is also expected to be a major factor for rising demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.

The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2017 and is expected to witness a CAGR of 3.7% during the forecast period (2018 – 2026).

North America is expected to hold dominant position, owing to frequent approvals of new cough suppressant drugs by FDA

North America cough suppressant market is expected to show good growth over the forecast period, owing to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.

Click to Read More On Cough Suppressant Drugs Market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.